Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study.
Multiple sclerosis
Tumefactive demyelinating lesions
Tumefactive multiple sclerosis
differential diagnosis
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
29
10
2020
accepted:
05
12
2020
pubmed:
12
12
2020
medline:
13
8
2021
entrez:
11
12
2020
Statut:
ppublish
Résumé
Tumefactive multiple sclerosis (TuMS) (i.e., MS onset presenting with tumefactive demyelinating lesions [TDLs]) is a diagnostic and therapeutic challenge. We performed a multicentre retrospective study to describe the clinical characteristics and the prognostic factors of TuMS. One hundred two TuMS patients were included in this retrospective study. Demographic, clinical, magnetic resonance imaging (MRI), laboratory data and treatment choices were collected. TuMS was found to affect women more than men (female:male: 2.4), with a young adulthood onset (median age: 29.5 years, range: 11-68 years, interquartile range [IQR]: 38 years). At onset, 52% of TuMS patients presented with the involvement of more than one functional system and 24.5% of them with multiple TDLs. TDLs most frequently presented with an infiltrative MRI pattern (38.7%). Cerebrospinal fluid immunoglobulin G oligoclonal bands were often demonstrated (76.6%). In 25.3% of the cases, more than one acute-phase treatment was administered, and almost one-half of the patients (46.6%) were treated with high-efficacy treatments. After a median follow-up of 2.3 years (range: 0.1-10.7 years, IQR: 3.4 years), the median Expanded Disability Status Scale (EDSS) score was 1.5 (range: 0-7, IQR: 2). Independent risk factors for reaching an EDSS score ≥3 were a higher age at onset (odds ratio [OR]: 1.08, 95% confidence interval [CI]: 1.03-1.14, p < 0.01), a higher number of TDLs (OR: 1.67, 95% CI: 1.02-2.74, p < 0.05) and the presence of infiltrative TDLs (OR: 3.34, 95% CI: 1.18-9.5, p < 0.001) at baseline. The management of TuMS might be challenging because of its peculiar characteristics. Large prospective studies could help to define the clinical characteristics and the best treatment algorithms for people with TuMS.
Sections du résumé
BACKGROUND AND PURPOSE
Tumefactive multiple sclerosis (TuMS) (i.e., MS onset presenting with tumefactive demyelinating lesions [TDLs]) is a diagnostic and therapeutic challenge. We performed a multicentre retrospective study to describe the clinical characteristics and the prognostic factors of TuMS.
METHODS
One hundred two TuMS patients were included in this retrospective study. Demographic, clinical, magnetic resonance imaging (MRI), laboratory data and treatment choices were collected.
RESULTS
TuMS was found to affect women more than men (female:male: 2.4), with a young adulthood onset (median age: 29.5 years, range: 11-68 years, interquartile range [IQR]: 38 years). At onset, 52% of TuMS patients presented with the involvement of more than one functional system and 24.5% of them with multiple TDLs. TDLs most frequently presented with an infiltrative MRI pattern (38.7%). Cerebrospinal fluid immunoglobulin G oligoclonal bands were often demonstrated (76.6%). In 25.3% of the cases, more than one acute-phase treatment was administered, and almost one-half of the patients (46.6%) were treated with high-efficacy treatments. After a median follow-up of 2.3 years (range: 0.1-10.7 years, IQR: 3.4 years), the median Expanded Disability Status Scale (EDSS) score was 1.5 (range: 0-7, IQR: 2). Independent risk factors for reaching an EDSS score ≥3 were a higher age at onset (odds ratio [OR]: 1.08, 95% confidence interval [CI]: 1.03-1.14, p < 0.01), a higher number of TDLs (OR: 1.67, 95% CI: 1.02-2.74, p < 0.05) and the presence of infiltrative TDLs (OR: 3.34, 95% CI: 1.18-9.5, p < 0.001) at baseline.
CONCLUSIONS
The management of TuMS might be challenging because of its peculiar characteristics. Large prospective studies could help to define the clinical characteristics and the best treatment algorithms for people with TuMS.
Substances chimiques
Oligoclonal Bands
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1299-1307Informations de copyright
© 2020 European Academy of Neurology.
Références
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. https://doi.org/10.1016/S1474-4422(17)30470-2
Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008;131(7):1759-1775. https://doi.org/10.1093/brain/awn098
Seewann A, Enzinger C, Filippi M, et al. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: a review of reported findings. J Neurol. 2008;255(1):1-10. https://doi.org/10.1007/s00415-007-0754-x
Malhotra HS, Jain KK, Agarwal A, et al. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy. Mult Scler. 2009;15(2):193-203. https://doi.org/10.1177/1352458508097922
Saini J, Chatterjee S, Thomas B, Kesavadas C. Conventional and advanced magnetic resonance imaging in tumefactive demyelination. Acta Radiol. 2011;52(10):1159-1168. https://doi.org/10.1258/ar.2011.110007
Balloy G, Pelletier J, Suchet L, et al. Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. J Neurol. 2018;265(10):2251-2259. https://doi.org/10.1007/s00415-018-8984-7
Totaro R, Di Carmine C, Splendiani A, et al. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis. Neurol Sci. 2016;37(7):1113-1117. https://doi.org/10.1007/s10072-016-2558-1
Friedman DI. Multiple sclerosis simulating a mass lesion. J Neuroophthalmol. 2000;20(3):147-153. http://www.ncbi.nlm.nih.gov/pubmed/11001187.
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. https://doi.org/10.1002/ana.22366
Frederick MC, Cameron MH. Tumefactive demyelinating lesions in multiple sclerosis and associated disorders. Curr Neurol Neurosci Rep. 2016;16(3):26. https://doi.org/10.1007/s11910-016-0626-9
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983;33(11):1444. https://doi.org/10.1212/WNL.33.11.1444
Siva A. Common clinical and imaging conditions misdiagnosed as multiple sclerosis: a current approach to the differential diagnosis of multiple sclerosis. Neurol Clin. 2018;36(1):69-117. https://doi.org/10.1016/j.ncl.2017.08.014
GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(3):269-285. https://doi.org/10.1016/S1474-4422(18)30443-5
Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012;11(2):157-169. https://doi.org/10.1016/S1474-4422(11)70274-5
Brownlee WJ, Miszkiel KA, Altmann DR, Ciccarelli O, Miller DH. Periventricular lesions and MS diagnostic criteria in young adults with typical clinically isolated syndromes. Mult Scler J. 2017;23(7):1031-1034. https://doi.org/10.1177/1352458516667565
Gastaldi M, Zardini E, Franciotta D. An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis. Expert Rev Mol Diagn. 2017;17(1):31-46. https://doi.org/10.1080/14737159.2017.1262260
Laroni A, Signori A, Maniscalco GT, et al. Assessing association of comorbidities with treatment choice and persistence in MS: a real-life multicenter study. Neurology. 2017;89(22):2222-2229. https://doi.org/10.1212/WNL.0000000000004686
Fernández O, Delvecchio M, Edan G, et al. Survey of diagnostic and treatment practices for multiple sclerosis in Europe. Eur J Neurol. 2017;24(3):516-522. https://doi.org/10.1111/ene.13236
Altintas A, Petek B, Isik N, et al. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Mult Scler. 2012;18(10):1448-1453. https://doi.org/10.1177/1352458512438237
Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006;63(12):1686-1691. https://doi.org/10.1001/archneur.63.12.1686
Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993;116(Pt 1):117-134. https://doi.org/10.1093/brain/116.1.117
Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126(Pt 4):770-782. http://www.ncbi.nlm.nih.gov/pubmed/12615637.
Guillemin F, Baumann C, Epstein J, et al. Older age at multiple sclerosis onset is an independent factor of poor prognosis: a population-based cohort study. Neuroepidemiology. 2017;48(3-4):179-187. https://doi.org/10.1159/000479516